ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2329

AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo
Abstract Number: 2041

An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic
Abstract Number: 1729

An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases
Abstract Number: 0764

An Atypical ClassRheum: RheumMadness, a Collaborative Rheumatology Competition Building Knowledge and Community
Abstract Number: 2323

An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health
Abstract Number: 2567

An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Abstract Number: 1020

An Increase in Safety Outcome Trials and the Issue of Informed Consent
Abstract Number: L13

An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results
Abstract Number: 1735

An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Abstract Number: 1929

Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience
Abstract Number: L01

Analysis of 245,388 Diverse Participants in the NIH All of Us Cohort Identifies VEXAS Resiliency in UBA1 M41L Somatic Mutation Carriers
Abstract Number: 0677

Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
Abstract Number: 1933

Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic
Abstract Number: 0577

Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
Abstract Number: 1409

Analysis of Soluble Biomarkers in Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].